Thomas Deuel - Net Worth and Insider Trading

Thomas Deuel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Thomas Deuel owns 1 companies in total, including Enzon Pharmaceuticals Inc (ENZN) .

Click here to see the complete history of Thomas Deuel’s form 4 insider trades.

Insider Ownership Summary of Thomas Deuel

Ticker	Comapny	Transaction Date	Type of Owner
ENZN	Enzon Pharmaceuticals Inc	2010-04-19	director

Thomas Deuel Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Thomas Deuel Ownership Network

Ownership Network List of Thomas Deuel

No Data

Ownership Network Relation of Thomas Deuel

Thomas Deuel Owned Company Details

What does Enzon Pharmaceuticals Inc do?

Who are the key executives at Enzon Pharmaceuticals Inc?

Thomas Deuel is the director of Enzon Pharmaceuticals Inc. Other key executives at Enzon Pharmaceuticals Inc include other: See Footnote 1 Family Fund Couchman , other: See explanation of responses Brian James Harper , and other: See explanation of responses Harper Asset Management Llc .

Enzon Pharmaceuticals Inc (ENZN) Insider Trades Summary

Over the past 18 months, Thomas Deuel made no insider transaction in Enzon Pharmaceuticals Inc (ENZN). Other recent insider transactions involving Enzon Pharmaceuticals Inc (ENZN) include a net purchase of 99,550 shares made by Randolph C Read ,

In summary, during the past 3 months, insiders sold 0 shares of Enzon Pharmaceuticals Inc (ENZN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Enzon Pharmaceuticals Inc (ENZN) were sold and 99,550 shares were bought by its insiders, resulting in a net purchase of 99,550 shares.

Enzon Pharmaceuticals Inc (ENZN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enzon Pharmaceuticals Inc Insider Transactions

No Available Data

Thomas Deuel Mailing Address

Above is the net worth, insider trading, and ownership report for Thomas Deuel. You might contact Thomas Deuel via mailing address: Imclone Systems Incorporated, 180 Varick Street, 6th Floor, New York Ny 10014.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.